Effects of Chemotherapy
Conditions
Keywords
lymphoma, consolidation chemotherapy, auto-HSCT
Brief summary
To imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical trial to test the efficacy and feasibility of consolidation chemotherapy after autologous stem cell transplantation
Detailed description
Patients with relapsed or refractory lymphoma will be included. All patients will undergo PBSC mobilization with CTX and G-CSF. After sucessful collection of CD34+ over 1x109/L, autologous stem cel ltransplantation with Bu-Cy-E conditioning will be given. Two months after auto-HSCT, a PET-CT will be performed and all patients with CR, CRu and PR will recieved 3 cycles of mini-Bu-Cy-E as consolidation 3, 6 and 9 months after auto-HSCT. For patients with SD or PD after auto-HSCT will refered to the allogeneic transplantatio program and take off the study.
Interventions
DRUGBu-CY-E
mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients with relapsed or refracotry NHL or HD: PR or SD after first line salvage chemotherapy; * ECOG: 0-2 * Tbil \< 1.5x ULN and AST/ALT \<2.5x ULN * With informed consent
Exclusion criteria
* Life expectancy \< 3 months * Women in pregnancy * uncontrollable infection disease * serum Cr \>400mmol/l * uncontroled diabetis and heart disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival | 2-year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 2-year | — |
| progression | 2-year | PET-CT measurement |
| transplantation-related mortality | 2-year | — |
Countries
China
Contacts
Primary ContactJiong Hu, M.D,
Outcome results
None listed